Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Burkitt Lymphoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Leukemia, Biphenotypic, Acute 3Down Syndrome 2Smoldering Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Breast Neoplasms 1

Interventions

Lenalidomide 3daratumumab 2Dexamethasone 2dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Maintenance 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Smoldering Multiple Myeloma × auricularum × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡